Citi upgraded QuidelOrtho (QDEL) to Buy from Neutral with a price target of $50, up from $44. The firm cites the company’s “attractive discounted valuation” and management’s commitment to re-aligning the cost structure and expanding margins for the upgrade. Heading into 2025, investor appetite for life science tools and diagnostics remains light, but there are “pockets of areas to be more constructive such as bioprocessing where the recovery is underway,” the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QDEL:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue